RT Journal Article
SR Electronic
T1 Evolving epidemiology of novel coronavirus diseases 2019 and possible interruption of local transmission outside Hubei Province in China: a descriptive and modeling study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.21.20026328
DO 10.1101/2020.02.21.20026328
A1 Zhang, Juanjuan
A1 Litvinova, Maria
A1 Wang, Wei
A1 Wang, Yan
A1 Deng, Xiaowei
A1 Chen, Xinghui
A1 Li, Mei
A1 Zheng, Wen
A1 Yi, Lan
A1 Chen, Xinhua
A1 Wu, Qianhui
A1 Liang, Yuxia
A1 Wang, Xiling
A1 Yang, Juan
A1 Sun, Kaiyuan
A1 Longini, Ira M.
A1 Halloran, M. Elizabeth
A1 Wu, Peng
A1 Cowling, Benjamin J.
A1 Merler, Stefano
A1 Viboud, Cecile
A1 Vespignani, Alessandro
A1 Ajelli, Marco
A1 Yu, Hongjie
YR 2020
UL http://medrxiv.org/content/early/2020/02/23/2020.02.21.20026328.abstract
AB Background The COVID-19 epidemic originated in Wuhan City of Hubei Province in December 2019 and has spread throughout China. Understanding the fast evolving epidemiology and transmission dynamics of the outbreak beyond Hubei would provide timely information to guide intervention policy.Methods We collected individual information on 8,579 laboratory-confirmed cases from official publically sources reported outside Hubei in mainland China, as of February 17, 2020. We estimated the temporal variation of the demographic characteristics of cases and key time-to-event intervals. We used a Bayesian approach to estimate the dynamics of the net reproduction number (Rt) at the provincial level.Results The median age of the cases was 44 years, with an increasing of cases in younger age groups and the elderly as the epidemic progressed. The delay from symptom onset to hospital admission decreased from 4.4 days (95%CI: 0.0-14.0) until January 27 to 2.6 days (0.0-9.0) from January 28 to February 17. The mean incubation period was estimated at 5.2 days (1.8-12.4) and the mean serial interval at 5.1 days (1.3-11.6). The epidemic dynamics in provinces outside Hubei was highly variable, but consistently included a mix of case importations and local transmission. We estimate that the epidemic was self-sustained for less than three weeks with Rt reaching peaks between 1.40 (1.04-1.85) in Shenzhen City of Guangdong Province and 2.17 (1.69-2.76) in Shandong Province. In all the analyzed locations (n=10) Rt was estimated to be below the epidemic threshold since the end of January.Conclusion Our findings suggest that the strict containment measures and movement restrictions in place may contribute to the interruption of local COVID-19 transmission outside Hubei Province. The shorter serial interval estimated here implies that transmissibility is not as high as initial estimates suggested.Competing Interest StatementB.J.C. has received honoraria from Roche and Sanofi Pasteur. A.V. has received funding from Metabiota Inc. H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. None of that research funding is related to COVID-19.Funding StatementH.Y. acknowledges financial support from the National Science Fund for Distinguished Young Scholars (No. 81525023), Key Emergency Project of Shanghai Science and Technology Committee (No. 20411950100), National Science and Technology Major Project of China (No. 2018ZX10201001-010, No. 2018ZX10713001-007, No. 2017ZX10103009-005). M.E.H acknowledges financial support from National Institute of General Medical Sciences U54 GM111274. S.M. and M.A. acknowledge financial support from the European Commission H2020 MOOD project.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll of our data is from public source.